Kiniksa Pharmaceuticals International, plc
KNSA
株式のランク
#2917
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
株価
$80.10
最終同期: 2026-10-21
時価総額
$6.25B
変化（1日）
-3.69%
変化（1年）
105.92%
国
GB
取引 Kiniksa Pharmaceuticals International, plc (KNSA)
カテゴリー
Healthcare
Kiniksa Pharmaceuticals International, plc（KNSA）の株価履歴
終値の最高値: $78.59 （2026-10-01）
終値の最安値: $18.08 （2018-05-01）
終値の最安値: $18.08 （2018-05-01）
Kiniksa Pharmaceuticals International, plc の株価履歴（2018 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 31.83% |
| 2025 | 101.55% |
| 2024 | 16.14% |
| 2023 | 13.98% |
| 2022 | 22.63% |
| 2021 | -31.53% |
| 2020 | 57.49% |
| 2019 | -47.95% |
| 2018 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $45.36 | 35.06% |
SE
|
|
| $170.70 | 23.42% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
